MEI, Kyowa stop lymphoma drug trials after FDA meeting
Bio Pharma Dive
DECEMBER 6, 2022
The decision not to run a Phase 3 trial of their medicine is the latest fallout from U.S. regulators’ recent moves to closely evaluate a class of drugs known as PI3 kinase inhibitors.
Let's personalize your content